<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001527" GROUP_ID="INJ" ID="165699072011520879" MERGED_FROM="" MODIFIED="2010-05-11 20:07:56 +0200" MODIFIED_BY="Emma Sydenham" REVIEW_NO="003" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.3">
<COVER_SHEET MODIFIED="2010-05-11 19:06:32 +0100" MODIFIED_BY="Emma Sydenham">
<TITLE>Aminosteroids for acute traumatic brain injury</TITLE>
<CONTACT>
<PERSON ID="8053" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Ian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Roberts</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Epidemiology &amp; Public Health</POSITION>
<EMAIL_1>ian.roberts@lshtm.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL>http://injuries.cochrane.org</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Injuries Group</DEPARTMENT>
<ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION>
<ADDRESS_1>North Courtyard</ADDRESS_1>
<ADDRESS_2>Keppel Street</ADDRESS_2>
<CITY>London</CITY>
<ZIP>WC1E 7HT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 7958 8128</PHONE_1>
<PHONE_2/>
<FAX_1>+44 20 7299 4663</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-05-11 19:06:32 +0100" MODIFIED_BY="Emma Sydenham">
<PERSON ID="8053" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Ian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Roberts</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Epidemiology &amp; Public Health</POSITION>
<EMAIL_1>ian.roberts@lshtm.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL>http://injuries.cochrane.org</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Injuries Group</DEPARTMENT>
<ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION>
<ADDRESS_1>North Courtyard</ADDRESS_1>
<ADDRESS_2>Keppel Street</ADDRESS_2>
<CITY>London</CITY>
<ZIP>WC1E 7HT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 7958 8128</PHONE_1>
<PHONE_2/>
<FAX_1>+44 20 7299 4663</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-07-17 22:43:21 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="1" MONTH="3" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="3" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="4" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2010-05-11 19:05:03 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2010-05-11 19:05:03 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>Aminosteroids are no longer produced. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-05-06 12:12:58 +0100" MODIFIED_BY="Emma M Sydenham">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-05-06 12:12:58 +0100" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="17" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-17 22:43:04 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="3" YEAR="2006"/>
<DESCRIPTION>
<P>An updated search for new trials was done in March 2006. No new trials for inclusion have been identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Institute of Child Health, University of London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-05-11 19:06:39 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Use of aminosteroids to treat traumatic brain injury</TITLE>
<SUMMARY_BODY>
<P>Traumatic brain injury is a leading cause of death and disability. After the initial blow to the head, additional brain damage can occur through a reduction of oxygen to the brain tissues (cerebral hypoxia). Chemicals called aminosteroids have been shown to help stop cell membrane damage and cell death in animals. </P>
<P>The review author searched the medical literature to find out if aminosteroids help people with traumatic brain injury when given within seven days of the injury. The author looked for randomised controlled trials in which one group of patients received a treatment (aminosteroids) while a similar group received non-active treatment (placebo) in addition to standard care. To reduce possible bias, each patient is randomly assigned to a group. The author found two such studies, which used the aminosteroid tirilazad mesylate, but the results of one of the studies were not available at the time of review. The completed study involved 1131 patients. The results of this study showed no benefit from the aminosteroid. The aminosteroid group did not have more side effects than the placebo group but aminosteroids are fairly new drugs that may have unknown less common side effects. </P>
<P>More research is needed on the use of aminosteroids to treat traumatic brain injury but currently there is no evidence to recommend their use.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-05-11 19:06:39 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Traumatic brain injury is a leading cause of premature death and disability. Post-traumatic membrane lipid peroxidation has been proposed as one mechanism leading to secondary brain damage following head injury. Aminosteroids have been shown to inhibit lipid peroxidation in laboratory animals and have the potential to improve outcome following head injury. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To quantify the effectiveness and safety of aminosteroids in the treatment of acute traumatic brain injury.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-05-11 19:06:39 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Injuries Group specialised register, the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, the National Research Register, Web of Science, web-based trials databases and conducted a general internet search. We contacted experts in the field and the company that manufactures tirilazad. The searches were last updated in March 2006.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We sought to identify all randomised controlled trials of aminosteroids versus placebo in the treatment of acute traumatic brain injury. Studies using a quasi-random form of allocation, such as alternation, were excluded from the review.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>One author examined the electronic search results for reports of possibly relevant trials for retrieval in full. Two authors (IR and PA) applied the selection criteria independently to the trial report, with no disagreement.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Two randomised controlled trials have examined the effect of the aminosteroid tirilazad mesylate on death and disability following head injury. To date, only the results of one of these trials are available for analysis. The risk of death in patients treated with tirilazad was almost identical to those given placebo RR = 1.05 (95% confidence interval 0.86 to 1.29). The risk of death and severe disability in patients treated with tirilazad was again almost identical to those given placebo RR = 1.07 (95% confidence interval 0.93 to 1.23).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is no evidence to support the routine use of aminosteroids in the management of traumatic head injury. On the basis of the existing evidence from randomised trials of aminosteroids in head injury, it is not possible to refute the possibility of moderate but potentially clinically important benefits or harms. A further randomised controlled trial of tirilazad mesylate with 1156 participants has been completed, the results of which should become available in the near future.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-17 22:49:53 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Traumatic brain injury is a leading cause of premature death and disability. Road crashes account for the majority of fatal head injuries (<LINK REF="REF-Jennet-1996" TYPE="REFERENCE">Jennet 1996</LINK>). Insights from pathophysiological studies have shown that acute traumatic head injury marks only the beginning of a continuing encephalopathic process. Secondary brain damage from on-going pathophysiological mechanisms and cerebral hypoxia is believed to be an important cause of avoidable death and long term disability. The modern management of head injury is primarily aimed at preventing secondary brain damage, which in turn requires an understanding of the pathophysiological processes involved in its development (<LINK REF="REF-Gentleman-1990" TYPE="REFERENCE">Gentleman 1990</LINK>). <LINK REF="REF-Demopoulos-1982" TYPE="REFERENCE">Demopoulos 1982</LINK> have proposed that the molecular basis for post-traumatic neuronal degeneration is oxygen free radical induced lipid peroxidation. Lipid peroxidation once initiated is considered to be a self-propagating process that leads to cell membrane damage and cell death. Tirilazad mesylate is a 21-aminosteroid that has been shown to inhibit lipid peroxidation in experimental animals (<LINK REF="REF-Hall-1988" TYPE="REFERENCE">Hall 1988</LINK>). There is considerable debate in the basic science community about whether or not the agent crosses the blood brain barrier: if it does not then any experimental protection would be because of lipid peroxidation in the vascular space, rather than cell membranes within the brain. Tirilazad has been evaluated in a number of randomised controlled trials. To assess the safety and effectiveness of aminosteroids in patients with head injury we conducted a systematic review of randomised controlled trials.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To quantify the effectiveness and safety of aminosteroids in the treatment of acute traumatic brain injury.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-17 22:49:53 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials of aminosteroids versus placebo (or no aminosteroid) for the treatment of acute traumatic brain injury.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People of all ages with clinically diagnosed acute traumatic brain injury secondary to head injury treated with aminosteroids within seven days of the injury. All severities of head injury were eligible. Trials in people with non-traumatic subarachnoid haemorrhage were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any regimen of any aminosteroid versus placebo, if started within seven days of head injury.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<UL>
<LI>All-cause fatality.</LI>
<LI>Any valid and reliable measure of neurological functioning.</LI>
<LI>Quality of life measures.</LI>
<LI>Side effects.</LI>
<LI>Economic outcomes were considered relevant if available.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-17 22:48:08 +0100" MODIFIED_BY="[Empty name]">
<P>There was no language restriction applied to the search.</P>
<P>An updated search was conducted in March 2006.</P>
<ELECTRONIC_SEARCHES MODIFIED="2008-07-17 22:47:00 +0100" MODIFIED_BY="[Empty name]">
<P>We searched:</P>
<UL>
<LI>the Cochrane Injuries Group's specialised register,</LI>
<LI>the Cochrane Central Register of Controlled Trials,</LI>
<LI>MEDLINE,</LI>
<LI>EMBASE,</LI>
<LI>the National Research Register.</LI>
</UL>
<P>Search strategies for each database are given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-07-17 22:48:08 +0100" MODIFIED_BY="[Empty name]">
<P>We searched relevant websites, and reference lists of all potentially eligible studies were examined for other relevant articles.</P>
<P>We also contacted an expert in the field and the company that manufactures tirilazad.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-17 22:49:53 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-07-17 22:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>One author examined the electronic search results for reports of possibly relevant trials for retrieval in full and applied the selection criteria to the trial report.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-07-17 22:49:07 +0100" MODIFIED_BY="[Empty name]">
<P>Information on the following was extracted: method of allocation concealment, number of randomised patients, type of participants and the interventions. The outcome data sought were as listed in the selection criteria. The reviewer was not blinded to the authors or journal when doing this, as evidence for the value of this is far from conclusive (<LINK REF="REF-Berlin-1997" TYPE="REFERENCE">Berlin 1997</LINK>).</P>
<P>Where there was insufficient information in the published report, the authors were contacted for clarification.</P>
<P>Disability was assessed using the Glasgow Outcome Scale, with a favourable outcome defined as good recovery (e.g. return to work) or moderate disability.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-17 22:49:53 +0100" MODIFIED_BY="[Empty name]">
<P>Since there is evidence that the quality of allocation concealment particularly affects the results of studies (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), the author scored this quality on the scale used by <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK> as shown below, assigning C to poorest quality and A to best quality:</P>
<UL>
<LI>C=trials in which concealment was inadequate (such as alternation or reference to case record numbers or to dates of birth)</LI>
</UL>
<UL>
<LI>B=trials in which the authors either did not report an allocation concealment approach at all or reported an approach that did not fall into one of the other categories</LI>
</UL>
<UL>
<LI>A=trials deemed to have taken adequate measures to conceal allocation (that is, central randomisation; numbered or coded bottles or containers; drugs prepared by the pharmacy; serially numbered, opaque, sealed envelopes; or other description that contained elements convincing of concealment)</LI>
</UL>
<P>Where the method used to conceal allocation was not clearly reported, the reviewer planned to contact the author, but this was not necessary.</P>
<P>Information on blinding and the degree of loss to follow up, was also collected but a score was not assigned to this.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-07-17 22:48:52 +0100" MODIFIED_BY="[Empty name]">
<P>The author planned to calculate summary statistics for the trial using intention to treat.</P>
<P>The author planned to examine trials for statistical evidence of heterogeneity using a chi squared test. If there was no obvious heterogeneity on visual inspection or statistical testing, pooled relative risks and 95% confidence intervals would be calculated using a fixed effects model. For continuous data, we would examine the mean and standard deviation to look for evidence of skewness as described by Altman (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>) and, if not present, calculate pooled weighted mean differences.</P>
<P>The effect of excluding trials judged to have inadequate (scoring C) allocation concealment was planned as a sensitivity analysis.</P>
<P>The author also intended to prepare funnel plots if there were sufficient trials to look for evidence of publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>
<LINK REF="STD-Marshall-1998" TYPE="STUDY">Marshall 1998</LINK>: The trial randomised 1131 patients to receive tirilazad mesylate or placebo. Eleven patients were excluded from the analysis because they did not complete their assigned protocol. Efforts to obtain these data from the study authors have so far been unsuccessful. A further 55 participants were lost before the six month follow up (38 in the tirilazad group and 28 in the placebo group). Data on side effects were collected from 1016 participants. Despite the use of random allocation, there were substantial pre-treatment imbalances in hypotension and hypoxia. </P>
<P>
<LINK REF="STD-Bleck" TYPE="STUDY">Bleck</LINK> (ongoing): A second randomised controlled trial of tirilazad mesylate in the treatment of head injury in 1156 patients has been conducted but the results are not yet available for inclusion in this review. </P>
<P>
<LINK REF="STD-Bleck-1995" TYPE="STUDY">Bleck 1995</LINK> (unpublished): Randomised double-blind vehicle controlled study of tirilazad mesylate at three escalating dosage tiers (0.6, 2.0, 6.0 mg/kg/day) in a total of 181 adults patients with Glasgow Coma Scores of 4 to 12 within four hours of closed head injury. Data were collected on mortality, GOS, and side effects. The study author was contacted to obtain the unpublished data and has agreed to discuss provision of the data with Pharmacia and Upjohn, as the material is covered by a confidentiality agreement. However, data on mortality were presented at conference and are in the public domain. These data have therefore been included. </P>
<P>
<LINK REF="STD-Mathew-1993" TYPE="STUDY">Mathew 1993</LINK> (unpublished): Thirty moderately head-injured patients shown by CT scan to have a focal intracranial lesion allocated to treatment with tirilazad or placebo in a randomised, double-blind protocol. Treatment commenced within 24 hours of injury and continued for four days. MR imaging with Gadolinium was performed at five days and the presence and extent of enhancement in the region of the lesion was measured. Also late MRI scans (six months) are being performed to detect if the ultimate resolution of a lesion is influenced by the therapy. The code was broken in the spring of 1993. The authors have been contacted for the unpublished data but, as yet, no data are available for inclusion.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<LINK REF="STD-Marshall-1998" TYPE="STUDY">Marshall 1998</LINK>: Allocation concealment was by the use of matching placebo. There were 66 participants excluded from the final analysis (about 6% of those randomised) - eleven due to protocol violation and 55 others lost to follow up. All personnel involved in the study were blinded to whether the patient received drug or placebo.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Two randomised controlled trials have examined the effect of the aminosteroid tirilazad mesylate on death and disability following head injury. To date, only the results of one of these trials are available for analysis. The risk of death in patients treated with tirilazad was almost identical to those given placebo RR=1.05 (95% confidence interval 0.86 to 1.29). The risk of death and disability in patients treated with tirilazad was again almost identical to those given placebo RR = 1.07 (95% confidence interval 0.93 to 1.23).</P>
<P>Because aminosteroids are new drugs, there was little information that could be used to predict the side effect profile. As a result, the side effects reported in this review were those reported in the trial itself. The criterion for reporting side effects in the trial was events that occurred in more than 2% of cases. There was no clear evidence of increased side effects in the aminosteroid treated group. However, the precision of the point estimates for many of the side effects was low and it is not possible to refute the possibility of clinically important adverse effects.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>There is no evidence that aminosteroids reduce the risk of death or disability following head injury. However, on the basis of the existing evidence it is not possible to refute the possibility of moderate but potentially clinically important benefits or harms.</P>
<P>The published trial (<LINK REF="STD-Marshall-1998" TYPE="STUDY">Marshall 1998</LINK>) pointed out that there were imbalances in some prognostic factors between treatment and control groups (pretreatment hypotension and hypoxia). It is not possible to tell what effect this confounding had on the overall result but it would be unlikely to make a major difference to the point estimate.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is no evidence to support the routine use of aminosteroids in the management of traumatic head injury.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>On the basis of the existing evidence from randomised trials of aminosteroids in head injury it is not possible to refute the possibility of moderate but potentially clinically important benefits or harms. A further randomised controlled trial of tirilazad mesylate with 1156 participants has been completed, the results of which should become available in the near future.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Thanks to Reinhard Wentz, Fiona Renton and Karen Blackhall for their help with searching.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Ian Roberts is a principal investigator in the MRC CRASH trial, a large simple randomised controlled trial of 48 hours of methylprednisolone in adults with head injury. Pharmacia Corporation are donating drug and placebo for the MRC CRASH trial but the design, management and finance of the study are entirely independent of them. Pharmacia Corporation also manufacture tirilazad. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>IR examined the search results and selected relevant trials, extracted data, contacted trialists and wrote the review. PA selected relevant trials, extracted data and helped to write the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-17 22:52:03 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Bleck-1995" NAME="Bleck 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Bleck TP, Germanson TP, Jane JA and the participants in the Tirilazad Head Trauma Trial, phase II. Tirilazad mesylate is safe in patients with moderate or severe head injury. Neurology 1995;45 (suppl 4):A345.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bleck TP, Germanson TP, Jane JA and the participants in the Tirilazad Head Trauma Trial, phase II</AU>
<TI>Tirilazad mesylate is safe in patients with moderate or severe head injury</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45</VL>
<NO>suppl 4</NO>
<PG>A345</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marshall-1998" NAME="Marshall 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Marshall LF, Maas AIR, Bowers Marshall S, Bricolo A, Fearnside M, Iannotti F et al. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J Neurosurg 1998;89:519-525.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marshall LF, Maas AIR, Bowers Marshall S, Bricolo A, Fearnside M, Iannotti F et al</AU>
<TI>A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1998</YR>
<VL>89</VL>
<PG>519-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Mathew-1993" NAME="Mathew 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Mathew P, Hadley D, Condon B, Teasdale GM. Blood Brain Barrier Permeability in head injured patients-effect of tirilazad mesylate. International Neurotrauma symposium 1993.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mathew P, Hadley D, Condon B, Teasdale GM</AU>
<TI>Blood Brain Barrier Permeability in head injured patients-effect of tirilazad mesylate</TI>
<SO>2nd International Neurotrauma symposium</SO>
<YR>1993</YR>
<PG>80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Bleck" NAME="Bleck" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;A second randomised controlled trial of Tirilazad mesylate in the treatment of head injury has been conducted but the results were not available for inclusion in this review.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Bleck T</AU>
<TI>Tirilazad mesylate in the treatment of head injury</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-17 22:52:03 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-17 22:52:03 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berlin-1997" NAME="Berlin 1997" TYPE="JOURNAL_ARTICLE">
<AU>Berlin JA for the University of Pennsylvania Meta-analysis blinding study</AU>
<TI>Does blinding of readers affect the results of meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>185-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Demopoulos-1982" MODIFIED="2008-07-17 22:51:28 +0100" MODIFIED_BY="[Empty name]" NAME="Demopoulos 1982" TYPE="JOURNAL_ARTICLE">
<AU>Demopoulos HB, Flamm ES, Seligman ML</AU>
<TI>Further studies on free radical pathology in the major central nervous system disorders: effects of very high doses of methylprednisolone on the functional outcome, morphology, and chemistry of experimental spinal cord impact injury</TI>
<SO>Canadian Journal of Physiology &amp; Pharmacology</SO>
<YR>1982</YR>
<VL>60</VL>
<PG>1415-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analyses detected by a simple graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gentleman-1990" MODIFIED="2008-07-17 22:51:31 +0100" MODIFIED_BY="[Empty name]" NAME="Gentleman 1990" TYPE="JOURNAL_ARTICLE">
<AU>Gentleman D</AU>
<TI>Preventing secondary brain damage after head injury: a multidisciplinary challenge</TI>
<SO>Injury</SO>
<YR>1990</YR>
<VL>21</VL>
<PG>305-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-1988" MODIFIED="2008-07-17 22:51:34 +0100" MODIFIED_BY="[Empty name]" NAME="Hall 1988" TYPE="JOURNAL_ARTICLE">
<AU>Hall ED, Yonkers PA, McCall JM, et al</AU>
<TI>Effects of the 21 aminosteroid U-74006F on experimental head injury in mice</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1988</YR>
<VL>68</VL>
<PG>456-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jennet-1996" MODIFIED="2008-07-17 22:51:53 +0100" MODIFIED_BY="[Empty name]" NAME="Jennet 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jennett B</AU>
<TI>Epidemiology of head injury</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1996</YR>
<VL>60</VL>
<NO>4</NO>
<PG>362-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-07-17 22:52:03 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bleck-1995">
<CHAR_METHODS>
<P>Randomised double-blind controlled study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult patients with GCS 4-12 within 4 hours after closed head injury.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tirilazad mesylate at three escalating dosage tiers (0.6, 2.0, 6.0 mg/kg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death at the end of the study period. Unpublished data on non-fatal outcome is being sought.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marshall-1998">
<CHAR_METHODS>
<P>Randomised double-blind placebo controlled trial. Randomisation stratified by severity of head injury as assessed on the Glasgow Coma Scale (4-8 severe, 9-12 moderate). About 1% of participants excluded due to protocol violations and about a further 5% were lost to follow up before the 6-month evaluation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1131 randomised patients with moderate and severe head injury. Patients were eligible for inclusion in the trial if the following criteria were met: Glasgow Coma Score 4-12, age between 15 and 65 years, abnormalities could be observed on computerised tomography scanning, treatment could be initiated within four hours from the time of injury.<BR/>Exclusion criteria: pregnancy, other investigational drugs taken within 30 days, any disease expected to make outcome meaurement difficult.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1) Tirilazad mesylate 10 mg/kg by i.v. infusion every 6 hours for 5 days. (n=562, excluding protocol violators)<BR/>2) Placebo. (n=558, excluding protocol violators)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death. Favourable outcome (good recovery and moderate disability) at six months as determined by the Glasgow Outcome Scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other treatment by 'standardised protocols'. Patients not allowed to be given calcium antagonists or megadose steroids.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Mathew-1993">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Bleck">
<CHAR_STUDY_NAME>
<P>North American phase III trial of tirilazad mesylate</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Patients with moderate and severe head injury</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tirilazad mesylate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death and disability</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Recruitment now complete (1156 randomised participants)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Thomas Bleck<BR/>Professor of Neurological Surgery and Internal Medicine<BR/>The University of Virginia<BR/>USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bleck-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Marshall-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Any aminosteroid at any dose versus no aminosteroid or placebo.</NAME>
<DICH_OUTCOME CHI2="0.0019157438221110937" CI_END="1.2818532857234262" CI_START="0.8704855629137846" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0563308094512065" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="147" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.10783832093399717" LOG_CI_START="-0.06023842730238995" LOG_EFFECT_SIZE="0.02379994681580363" METHOD="MH" NO="1" P_CHI2="0.9650883782419027" P_Q="0.0" P_Z="0.5788479377102898" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="642" TOTAL_2="598" WEIGHT="100.0" Z="0.5550683135223243">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.987951937200083" CI_START="0.5761082287473447" EFFECT_SIZE="1.0701754385964912" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" LOG_CI_END="0.29840588023175957" LOG_CI_START="-0.23949592155520827" LOG_EFFECT_SIZE="0.02945497933827563" ORDER="31300" O_E="0.0" SE="0.31596618102652657" STUDY_ID="STD-Bleck-1995" TOTAL_1="114" TOTAL_2="61" VAR="0.09983462755248777" WEIGHT="10.458175052329636"/>
<DICH_DATA CI_END="1.2929151888283998" CI_START="0.8603976652651997" EFFECT_SIZE="1.0547138047138047" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="135" LOG_CI_END="0.11157003746208888" LOG_CI_START="-0.06530077676413829" LOG_EFFECT_SIZE="0.023134630348975255" ORDER="31301" O_E="0.0" SE="0.10389479180113653" STUDY_ID="STD-Marshall-1998" TOTAL_1="528" TOTAL_2="537" VAR="0.010794127763401506" WEIGHT="89.54182494767036"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.23364898381819" CI_START="0.9324374953469162" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0725206611570248" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="220" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.09119160534014319" LOG_CI_START="-0.03038027087126964" LOG_EFFECT_SIZE="0.030405667234436797" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.3268929517635396" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="528" TOTAL_2="537" WEIGHT="100.0" Z="0.9803914287178069">
<NAME>Death or disability (GOS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.23364898381819" CI_START="0.9324374953469162" EFFECT_SIZE="1.0725206611570248" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="220" LOG_CI_END="0.09119160534014319" LOG_CI_START="-0.03038027087126964" LOG_EFFECT_SIZE="0.030405667234436797" ORDER="31302" O_E="0.0" SE="0.07141192187707672" STUDY_ID="STD-Marshall-1998" TOTAL_1="528" TOTAL_2="537" VAR="0.005099662586177708" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.351642021227179" CI_START="0.4073062604565981" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7419786096256684" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.13086168510300872" LOG_CI_START="-0.390078914586579" LOG_EFFECT_SIZE="-0.12960861474178514" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.32942760199489673" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="0.9752674954933193">
<NAME>Sepsis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3516420212271787" CI_START="0.4073062604565981" EFFECT_SIZE="0.7419786096256684" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" LOG_CI_END="0.13086168510300863" LOG_CI_START="-0.390078914586579" LOG_EFFECT_SIZE="-0.12960861474178514" ORDER="31303" O_E="0.0" SE="0.30600308695522094" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.09363788922612451" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.055423099683488" CI_START="0.5878601103730058" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0992275698158052" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.3129012329977286" LOG_CI_START="-0.2307260081433486" LOG_EFFECT_SIZE="0.04108761242718998" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.7670238410317504" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="0.2962700706425204">
<NAME>Cardiac arrest</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.055423099683488" CI_START="0.5878601103730058" EFFECT_SIZE="1.0992275698158052" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.3129012329977286" LOG_CI_START="-0.2307260081433486" LOG_EFFECT_SIZE="0.04108761242718998" ORDER="31304" O_E="0.0" SE="0.3193293324445123" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.10197122255945786" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0593638546211044" CI_START="0.5365189121287952" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0511363636363635" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.31373308585727777" LOG_CI_START="-0.27041496467954995" LOG_EFFECT_SIZE="0.021659060588863938" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.884439894077126" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="0.14534321788502788">
<NAME>hypotension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0593638546211044" CI_START="0.5365189121287952" EFFECT_SIZE="1.0511363636363635" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.31373308585727777" LOG_CI_START="-0.27041496467954995" LOG_EFFECT_SIZE="0.021659060588863938" ORDER="31305" O_E="0.0" SE="0.3431314564648176" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.117739196415667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.156312047983015" CI_START="0.8401656499533849" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8686868686868687" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.6187081461107573" LOG_CI_START="-0.07563507849982963" LOG_EFFECT_SIZE="0.2715365338054639" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.12528455257070534" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="1.5329647006897211">
<NAME>multiple organ failure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.156312047983015" CI_START="0.8401656499533849" EFFECT_SIZE="1.8686868686868687" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.6187081461107573" LOG_CI_START="-0.07563507849982963" LOG_EFFECT_SIZE="0.2715365338054639" ORDER="31306" O_E="0.0" SE="0.40786064719065274" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.16635030752677812" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4610281843602813" CI_START="0.6383675205728889" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9657499363381716" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.16465859389054785" LOG_CI_START="-0.1949292175138482" LOG_EFFECT_SIZE="-0.015135311811650135" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.8689497975342669" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="0.16499261156689635">
<NAME>brain edema</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4610281843602813" CI_START="0.638367520572889" EFFECT_SIZE="0.9657499363381716" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="42" LOG_CI_END="0.16465859389054785" LOG_CI_START="-0.19492921751384812" LOG_EFFECT_SIZE="-0.015135311811650135" ORDER="31307" O_E="0.0" SE="0.21122366040731594" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.04461543471586513" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7007130011341614" CI_START="0.5754786445709972" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9893048128342246" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.23063103169607552" LOG_CI_START="-0.23997078796304597" LOG_EFFECT_SIZE="-0.004669878133485187" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.9689715140529893" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="0.03889824718676985">
<NAME>intraparenchymal haemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7007130011341614" CI_START="0.5754786445709972" EFFECT_SIZE="0.9893048128342246" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.23063103169607552" LOG_CI_START="-0.23997078796304597" LOG_EFFECT_SIZE="-0.004669878133485187" ORDER="31308" O_E="0.0" SE="0.2764338383843452" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.0764156670039023" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.425251140946486" CI_START="0.4802646792846616" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0792416140009722" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.38475671756914864" LOG_CI_START="-0.31851935205731946" LOG_EFFECT_SIZE="0.03311868275591458" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.8535449181732413" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="0.18459728183692306">
<NAME>epidural haematoma</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.425251140946486" CI_START="0.4802646792846616" EFFECT_SIZE="1.0792416140009722" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.38475671756914864" LOG_CI_START="-0.31851935205731946" LOG_EFFECT_SIZE="0.03311868275591458" ORDER="31309" O_E="0.0" SE="0.41310784457127725" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.17065809124632655" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.413221433290209" CI_START="0.5980050358554891" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2012987012987013" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.38259717389545667" LOG_CI_START="-0.22329515876235514" LOG_EFFECT_SIZE="0.07965100756655073" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.6063319926063264" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="0.5153163284901127">
<NAME>cerebral infarction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.413221433290209" CI_START="0.5980050358554891" EFFECT_SIZE="1.2012987012987013" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.38259717389545667" LOG_CI_START="-0.22329515876235514" LOG_EFFECT_SIZE="0.07965100756655073" ORDER="31310" O_E="0.0" SE="0.3559041554186161" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.12666776784423842" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1014810298511857" CI_START="0.4865714931334443" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7320855614973262" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.04197702195714952" LOG_CI_START="-0.31285333876216753" LOG_EFFECT_SIZE="-0.135438158402509" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.13459373330203372" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="1.496229984735335">
<NAME>brain herniation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1014810298511857" CI_START="0.4865714931334443" EFFECT_SIZE="0.7320855614973262" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="50" LOG_CI_END="0.04197702195714952" LOG_CI_START="-0.31285333876216753" LOG_EFFECT_SIZE="-0.135438158402509" ORDER="31311" O_E="0.0" SE="0.20842911032513986" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.043442694030929326" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2077095159481317" CI_START="0.7540390965090953" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9542851734418627" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="113" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.08196248826576964" LOG_CI_START="-0.1226061356183321" LOG_EFFECT_SIZE="-0.020321823676281242" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.6969764300731924" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="0.38940519566920767">
<NAME>intracranial hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2077095159481317" CI_START="0.7540390965090953" EFFECT_SIZE="0.9542851734418627" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="113" LOG_CI_END="0.08196248826576964" LOG_CI_START="-0.1226061356183321" LOG_EFFECT_SIZE="-0.020321823676281242" ORDER="31312" O_E="0.0" SE="0.12016462230054109" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.014439536452631697" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.583851426683151" CI_START="0.5230238079094944" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9101604278074866" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.19971444013356468" LOG_CI_START="-0.2814785417094245" LOG_EFFECT_SIZE="-0.0408820507879299" METHOD="MH" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.7391069392010048" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="0.3330362253064825">
<NAME>pneumonia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5838514266831507" CI_START="0.5230238079094945" EFFECT_SIZE="0.9101604278074866" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" LOG_CI_END="0.19971444013356465" LOG_CI_START="-0.28147854170942443" LOG_EFFECT_SIZE="-0.0408820507879299" ORDER="31313" O_E="0.0" SE="0.28265513947824744" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.07989392787346752" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.5261469838179993" CI_START="0.6716312341331578" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5389185977421271" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.5473004114603636" LOG_CI_START="-0.1728691152495076" LOG_EFFECT_SIZE="0.18721564810542798" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.30819038479364846" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="555" WEIGHT="100.0" Z="1.0190265320037286">
<NAME>ARDS</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aminosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5261469838179993" CI_START="0.6716312341331578" EFFECT_SIZE="1.5389185977421271" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.5473004114603636" LOG_CI_START="-0.1728691152495076" LOG_EFFECT_SIZE="0.18721564810542798" ORDER="31314" O_E="0.0" SE="0.42303114488602944" STUDY_ID="STD-Marshall-1998" TOTAL_1="561" TOTAL_2="555" VAR="0.17895534954358483" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-07-17 22:45:50 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-07-17 22:45:50 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-07-17 22:44:51 +0100" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-17 22:45:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>CENTRAL, MEDLINE, National Research Register</B>
<BR/>#1 TIRILAZAD in MeSH<BR/>#2 PREGNATRIENES in MeSH<BR/>#3 AMINOSTEROIDS in MeSH<BR/>#4 lazaroid* OR antioxidan* OR aminosteroid*<BR/>#5 #1 OR #2 OR #3 OR #4<BR/>#6 CRANIOCEREBRAL TRAUMA in MeSH<BR/>#7 (head OR brain) AND (injur* OR trauma*)<BR/>#8 #6 OR #7<BR/>#9 #8 AND #5<BR/>#10 RCT filter (Clarke 2001)</P>
<P>
<B>EMBASE</B>
<BR/>#1 TIRILAZAD/<BR/>#2 PREGNATRIENES/<BR/>#3 AMINOSTEROIDS/<BR/>#4 lazaroid$ OR antioxidan$ OR aminosteroid$<BR/>#5 #1 OR #2 OR #3 OR #4<BR/>#6 HEAD INJURY/<BR/>#7 (head OR brain) AND (injur$ OR trauma$)<BR/>#8 #6 OR #7<BR/>#9 #8 AND #5</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>